{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:47:29Z","timestamp":1791406049419,"version":"4.3.3"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology, Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Health, Labour, and Welfare, Japan"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide. Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clinically available as anti-HBV agents, emergence of drug-resistant viruses highlights the need for new anti-HBV agents interfering with other targets. Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes. The anti-HBV effect of CsA was independent of binding to cyclophilin and calcineurin. Rather, blockade of HBV infection correlated with the ability to inhibit the transporter activity of sodium taurocholate cotransporting polypeptide (NTCP). We also found that HBV infection-susceptible cells, differentiated HepaRG cells and primary human hepatocytes expressed NTCP, while nonsusceptible cell lines did not. A series of compounds targeting NTCP could inhibit HBV infection. CsA inhibited the binding between NTCP and large envelope protein<\/jats:bold>\n                                 <jats:bold>\n                                    in vitro\n                                 <\/jats:bold>\n                                 <jats:bold>. Evaluation of CsA analogs identified a compound with higher anti-HBV potency, having a median inhibitory concentration &lt;0.2 \u03bcM.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion :<\/jats:title>\n            <jats:p>\n                                 <jats:bold>This study provides a proof of concept for the novel strategy to identify anti-HBV agents by targeting the candidate HBV receptor, NTCP, using CsA as a structural platform. (Hepatology 2014;59:1726\u20131737)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26982","type":"journal-article","created":{"date-parts":[[2013,12,21]],"date-time":"2013-12-21T05:40:41Z","timestamp":1387604441000},"page":"1726-1737","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":250,"title":["Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP)"],"prefix":"10.1097","volume":"59","author":[{"given":"Koichi","family":"Watashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Sluder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Daito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Ryo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushi","family":"Nagamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syo","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senko","family":"Tsukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyna","family":"Borroto-Esoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikatsu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20250207","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.","volume":"134","author":"Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"key":"R2-15-20250207","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/jmv.10096","article-title":"Viral determinants and host immune responses in the pathogenesis of HBV infection.","volume":"67","author":"Rapicetta","year":"2002","journal-title":"J Med Virol"},{"issue":"Suppl 1","key":"R3-15-20250207","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1478-3231.2010.02399.x","article-title":"Hepatitis B virus resistance to antiviral drugs: where are we going?","volume":"31","author":"Zoulim","year":"2011","journal-title":"Liver Int"},{"key":"R4-15-20250207","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s12072-011-9261-3","article-title":"HBV life cycle and novel drug targets.","volume":"5","author":"Grimm","year":"2011","journal-title":"Hepatol Int"},{"key":"R5-15-20250207","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","article-title":"Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein.","volume":"79","author":"Gripon","year":"2005","journal-title":"J Virol"},{"key":"R6-15-20250207","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat Biotechnol"},{"key":"R7-15-20250207","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT61 and AT130 inhibit replication of wildtype and lamivudineresistant strains of hepatitis B virus in vitro.","volume":"46","author":"Delaney WEt, Edwards","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-15-20250207","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by druginduced depletion of nucleocapsids.","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"R9-15-20250207","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.42.12.3179","article-title":"Inhibition of human hepatitis B virus replication by AT61, a phenylpropenamide derivative, alone and in combination with ()betaL2,3dideoxy3thiacytidine.","volume":"42","author":"King","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-15-20250207","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0166-3542(01)00216-9","article-title":"Inhibition of human hepatitis B virus (HBV) by a novel nonnucleosidic compound in a transgenic mouse model.","volume":"54","author":"Weber","year":"2002","journal-title":"Antiviral Res"},{"key":"R11-15-20250207","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nm0598-610","article-title":"Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.","volume":"4","author":"Block","year":"1998","journal-title":"Nat Med"},{"key":"R12-15-20250207","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1073\/pnas.91.6.2235","article-title":"Secretion of human hepatitis B virus is inhibited by the imino sugar Nbutyldeoxynojirimycin.","volume":"91","author":"Block","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-15-20250207","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/117739280700200017","article-title":"Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible antiviral target.","volume":"2","author":"Watashi","year":"2007","journal-title":"Drug Target Insights"},{"key":"R14-15-20250207","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1021\/jm0109863","article-title":"Cyclosporins: structureactivity relationships for the inhibition of the human MDR1 Pglycoprotein ABC transporter.","volume":"45","author":"Loor","year":"2002","journal-title":"J Med Chem"},{"key":"R15-15-20250207","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1348-0421.2007.tb03883.x","article-title":"In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin.","volume":"51","author":"ElFarrash","year":"2007","journal-title":"Microbiol Immunol"},{"key":"R16-15-20250207","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"R17-15-20250207","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1053\/j.gastro.2005.06.031","article-title":"Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.","volume":"129","author":"Nakagawa","year":"2005","journal-title":"Gastroenterology"},{"key":"R18-15-20250207","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molcel.2005.05.014","article-title":"Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.","volume":"19","author":"Watashi","year":"2005","journal-title":"Mol Cell"},{"key":"R19-15-20250207","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1128\/JVI.02614-07","article-title":"Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.","volume":"82","author":"Yang","year":"2008","journal-title":"J Virol"},{"key":"R20-15-20250207","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/474S5a","article-title":"Therapeutics: new drugs hit the target.","volume":"474","author":"Schlutter","year":"2011","journal-title":"Nature"},{"key":"R21-15-20250207","first-page":"213","article-title":"Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.","volume":"11","author":"Watashi","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"R22-15-20250207","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"R23-15-20250207","doi-asserted-by":"crossref","first-page":"31715","DOI":"10.1074\/jbc.M113.501122","article-title":"Interleukin1 and tumor necrosis factoralpha trigger restriction of hepatitis b virus infection via a cytidine deaminase activationinduced cytidine deaminase (AID).","volume":"288","author":"Watashi","year":"2013","journal-title":"J Biol Chem"},{"key":"R24-15-20250207","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bbrc.2013.09.100","article-title":"Specific inhibition of hepatitis C virus entry into host hepatocytes by fungiderived sulochrin and its derivatives.","volume":"440","author":"Nakajima","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"R25-15-20250207","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.105.008748","article-title":"Inhibition of bile acid transport across Nataurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)coexpressing LLCPK1 cells by cholestasisinducing drugs.","volume":"34","author":"Mita","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R26-15-20250207","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nprot.2009.207","article-title":"Practical cellfree protein synthesis system using purified wheat embryos.","volume":"5","author":"Takai","year":"2010","journal-title":"Nat Protoc"},{"key":"R27-15-20250207","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus.","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R28-15-20250207","first-page":"122","article-title":"Role of glycosaminoglycans for binding and infection of hepatitis B virus.","volume":"10","author":"Leistner","year":"2008","journal-title":"Cell Microbiol"},{"key":"R29-15-20250207","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/hep.21896","article-title":"Hepatitis B virus infection initiates with a large surface proteindependent binding to heparan sulfate proteoglycans.","volume":"46","author":"Schulze","year":"2007","journal-title":"Hepatology"},{"key":"R30-15-20250207","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.21297","article-title":"pHindependent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes.","volume":"44","author":"Funk","year":"2006","journal-title":"Hepatology"},{"key":"R31-15-20250207","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/v2061279","article-title":"Antiviral treatment of chronic hepatitis B virus (HBV) infections.","volume":"2","author":"De Clercq","year":"2010","journal-title":"Viruses"},{"issue":"Suppl 3","key":"R32-15-20250207","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3851\/IMP1619","article-title":"Molecular genetics of HBV infection.","volume":"15","author":"Locarnini","year":"2010","journal-title":"Antivir Ther"},{"key":"R33-15-20250207","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-15-20250207","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1128\/JVI.02530-07","article-title":"Critical role of virionassociated cholesterol and sphingolipid in hepatitis C virus infection.","volume":"82","author":"Aizaki","year":"2008","journal-title":"J Virol"},{"key":"R35-15-20250207","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-3565(24)35228-0","article-title":"Modulation by drugs of human hepatic sodiumdependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.","volume":"291","author":"Kim","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R36-15-20250207","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/jpet.106.119073","article-title":"Differential inhibition of rat and human Nadependent taurocholate cotransporting polypeptide (NTCPSLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity.","volume":"321","author":"Leslie","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R37-15-20250207","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","article-title":"Function of the Srcfamily kinases, Lck and Fyn, in Tcell development and activation.","volume":"23","author":"Palacios","year":"2004","journal-title":"Oncogene"},{"key":"R38-15-20250207","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/hep.21102","article-title":"The nonimmunosuppressive cyclosporin DEBIO025 is a potent inhibitor of hepatitis C virus replication in vitro.","volume":"43","author":"Paeshuyse","year":"2006","journal-title":"Hepatology"},{"key":"R39-15-20250207","doi-asserted-by":"crossref","first-page":"e1000524","DOI":"10.1371\/journal.ppat.1000524","article-title":"Target cell cyclophilins facilitate human papillomavirus type 16 infection.","volume":"5","author":"BienkowskaHaba","year":"2009","journal-title":"PLoS Pathog"},{"key":"R40-15-20250207","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1099\/vir.0.19074-0","article-title":"Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype.","volume":"84","author":"Bose","year":"2003","journal-title":"J Gen Virol"},{"key":"R42-15-20250207","doi-asserted-by":"crossref","first-page":"e37277","DOI":"10.1371\/journal.pone.0037277","article-title":"Cyclosporin A inhibits the influenza virus replication through cyclophilin Adependent and independent pathways.","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"R43-15-20250207","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0092-8674(93)90637-6","article-title":"Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.","volume":"73","author":"Luban","year":"1993","journal-title":"Cell"},{"key":"R44-15-20250207","doi-asserted-by":"crossref","first-page":"e1002331","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARScoronavirushost interactome: identification of cyclophilins as target for pancoronavirus inhibitors.","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PLoS Pathog"},{"key":"R45-15-20250207","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1128\/AAC.00189-09","article-title":"Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.","volume":"53","author":"Qing","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R46-15-20250207","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm910","article-title":"Cyclophilin A modulates the sensitivity of HIV1 to host restriction factors.","volume":"9","author":"Towers","year":"2003","journal-title":"Nat Med"},{"key":"R47-15-20250207","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1128\/JVI.77.14.7713-7719.2003","article-title":"Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication.","volume":"77","author":"Bouchard","year":"2003","journal-title":"J Virol"},{"key":"R48-15-20250207","first-page":"18","article-title":"Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms.","volume":"4","author":"Xia","year":"2005","journal-title":"Hepatobil Pancreat Dis Int"},{"issue":"Suppl 1","key":"R49-15-20250207","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2893.2007.00916.x","article-title":"Management of hepatitis B in liver transplant recipients.","volume":"14","author":"Coffin","year":"2007","journal-title":"J Viral Hepat"},{"key":"R50-15-20250207","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2011.08.026","article-title":"The option of HBIGfree prophylaxis against recurrent HBV.","volume":"56","author":"Fox","year":"2012","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26982","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.26982","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.26982","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201405000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:55:51Z","timestamp":1738947351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201405000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26982","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}